预约演示
更新于：2025-03-25
Atosiban acetate
醋酸阿托西班
更新于：2025-03-25
概要
基本信息
药物类型 合成多肽 |
别名 Antocile、Antocin、Antocin II + [21] |
作用方式 拮抗剂 |
作用机制 AVPR拮抗剂(血管加压素受体家族拮抗剂)、OXTR拮抗剂(催产素受体拮抗剂) |
治疗领域 |
在研适应症 |
非在研适应症 |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 欧盟 (2000-01-20), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C43H67N11O12S2.C2H4O2 |
InChIKeySVDWBHHCPXTODI-QIWYXCRTSA-N |
CAS号914453-95-5 |
Sequence Code 15073107
关联
34
项与 醋酸阿托西班 相关的临床试验CTRI/2024/11/076392
A Randomized controlled trial to evaluate the efficacy of Atosiban in patients undergoing Embryo transfer. - NIL
NL-OMON47936
Atosiban as a potential treatment for endometriosis - ENDOBAN pilot-study
NCT05382143
The Effect of Selective Oxytocin Receptor Inhibitors on Endometriosis-related Pain
100 项与 醋酸阿托西班 相关的临床结果
登录后查看更多信息
100 项与 醋酸阿托西班 相关的转化医学
登录后查看更多信息
100 项与 醋酸阿托西班 相关的专利（医药）
登录后查看更多信息
668
项与 醋酸阿托西班 相关的文献（医药）2025-03-01BRAIN RESEARCH
Combination of rTMS and oxytocin agonist attenuate depression-like behavior after postpartum depression in mice
Article
作者: Fang, Marong ; Yuan, Xia ; Amin, Nashwa ; Hu, Zhiying ; Abbasi, Irum Naz ; Wu, Fei ; Ye, Qing ; Sundus, Javaria ; Hussein, Azhar B ; Chen, Shijia
The Diagnostic and Statistical Manual of Mental Disorders (DSM-5) categorizes postpartum depression (PPD) as a subtype of Major Depressive Disorder (MDD) with peripartum onset, generally arising within the initial trimester following delivery. This acute psychiatric condition is characterized by feelings of worthlessness, insomnia, extreme anxiety, or maternal neglect. Intranasal oxytocin (OT) and transcranial magnetic stimulation (TMS) have the potential to address impaired social cognition; nonetheless, their neuronal underpinnings, along with their safety and efficacy, are little comprehended. This study examines the effects of rTMS stimulation with an oxytocin agonist or antagonist in a PPD model. We employed the maternal separation with early weaning (MSEW) strategy for 21 days to attain our objective. Oxytocin acetate (agonist) and atosiban (antagonist) were administered by injection twice daily for three consecutive days following the model according to the established protocol. A single session of rTMS involved the application of high-frequency stimulation (20 Hz) one hour following the final injection. Behavioral testing and brain collection were conducted 12 h post-rTMS. The results indicated that treatment with OT followed by rTMS stimulation decreased neuronal cell death and microglial activation, meanwhile enhancing synaptic plasticity through the upregulation of PSD95, Synapsin I, and Synaptophysin. Simultaneously, both OT therapy and repetitive transcranial magnetic stimulation demonstrated a significant capacity to alter autophagy activity and astrocyte function. Nonetheless, OTA therapy followed by rTMS did not exhibit the same pattern of outcomes. Our findings indicate that the combination of rTMS stimulation and an oxytocin agonist in a PPD model may mitigate depression-like behavior.
2025-02-01NEUROCHEMICAL RESEARCH
Oxytocin Protects Against Corticosterone-Induced DA Dysfunction: An Involvement of the PKA/CREB Pathway
Article
作者: Sookkua, Tichaporn ; Chaipunko, Sirinun ; Nopparat, Chutikorn ; Chutabhakdikul, Nuanchan
Abstract:
Chronic stress disrupts dopamine (DA) transmission, adversely affecting mood and contribution to neuropsychiatric disorders like ADHD, autism, schizophrenia, anxiety, depression, and drug addiction. The neuropeptide oxytocin (OXT) plays a key role in social cognition, bonding, attachment, and parenting behaviors. In addition, OXT can modulate the activity of the HPA axis, counteracting the effects of stress, and alleviating fear and anxiety. However, whether OXT can mitigate stress-induced DA dysfunction and the underlying mechanisms remains unclear. This study investigated the neuroprotective effects of OXT on corticosterone (CORT) induced DA dysfunction in the neuroblastoma cell line SH-SY5Y. The results revealed that CORT decreases the levels of intracellular signaling molecules associated with DA function, including phosphorylated tyrosine hydroxylase (pTH), phosphorylated cAMP response element-binding protein (pCREB), and protein kinase A (PKA). Interestingly, pretreatment with OXT mitigated CORT-induced DA dysfunction through its potent PKA activator properties. In addition, the neuroprotective effect of OXT was abolished by atosiban (an OXT receptor antagonist) or H89 (a PKA inhibitor). Our results suggest that OXT protects dopaminergic neuroblastoma cells from CORT-induced DA dysfunction, potentially through the involvement of oxytocin receptors and the PKA/CREB signaling pathway. These findings contribute to the understanding of the neurobiological mechanisms underlying stress resilience and highlight potential pathways for developing targeted treatments that leverage the neuroprotective properties of OXT to address disorders characterized by DA dysregulation and impaired stress responses.
2025-01-01GEBURTSHILFE UND FRAUENHEILKUNDE
Differences between Current Clinical Practice and Evidence-Based Guideline Recommendations Regarding Tocolysis – an Austria-wide Survey
Article
作者: Stroemer, Annika ; Mayr, Andreas ; Stelzl, Patrick ; Eichinger, Teresa ; Oppelt, Peter ; Kehl, Sven ; Enengl, Sabine ; Rath, Werner ; Lastinger, Julia
Abstract:
To evaluate the adherence of Austrian obstetricians to national guideline recommendations by investigating data on the current practice of tocolysis regarding indications, timing and monitoring of tocolysis, choice of tocolytics and serious side effects, maintenance tocolysis, support of decision-making and recommendations at patient’s discharge from the hospital.78 obstetric departments in Austria were invited to participate in a nationwide survey between June 5th and August 31st 2023 by answering a web-based questionnaire about clinical standards. The survey was conducted approximately one year after implementation of the AWMF Guideline “Prevention and Therapy of Preterm Birth” 015‑025. Collected data were analyzed descriptively by performing measures of frequency. Fisher’s exact test was used for group comparison.The response rate was 69.2% (33.3% perinatal centers, 66.7% standard care). The most important indication of tocolysis were ≥ 4 contractions within 20 minutes of CTG tracing, as stated by 26 (48.1%) of the respondents; the AWMF Guideline 015‑025 (2022) was the most important decision-making support for tocolytic treatment (61.1%). 19 (35.2%) of obstetric units started tocolysis earliest at 23 + 0 weeks of gestation. Atosiban was the first-line tocolytic drug used by 43 (79.6%) of obstetric units, followed by nifedipine (n = 7, 13.0%); 49 of 54 obstetric units (90.7%) stated to perform maintenance tocolysis, among these 46 (93.9%) not routinely but on special indications (e.g. placenta previa). Serious side effects were observed by 77.8% of the respondents, mostly associated with the use of hexoprenaline.Our survey revealed considerable discrepancies between evidence-based guideline recommendations and daily clinical practice in Austrian hospitals.
100 项与 醋酸阿托西班 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 早产 | 欧盟 | 2000-01-20 | |
| 早产 | 冰岛 | 2000-01-20 | |
| 早产 | 列支敦士登 | 2000-01-20 | |
| 早产 | 挪威 | 2000-01-20 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 1型阵发性家族性心室颤动 | 临床2期 | 比利时 | 2007-11-01 | |
| 1型阵发性家族性心室颤动 | 临床2期 | 捷克 | 2007-11-01 | |
| 1型阵发性家族性心室颤动 | 临床2期 | 西班牙 | 2007-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | - | 194 | 製糧糧艱壓膚艱憲鹽鑰(襯構願顧夢窪膚衊膚積) = 觸膚醖蓋艱夢選鏇衊夢 淵襯壓憲願積糧糧醖構 (膚遞構觸積願糧醖廠顧 ) | - | 2022-08-19 | ||
Placebo | 製糧糧艱壓膚艱憲鹽鑰(襯構願顧夢窪膚衊膚積) = 製顧觸鏇選廠簾衊範積 淵襯壓憲願積糧糧醖構 (膚遞構觸積願糧醖廠顧 ) | ||||||
N/A | 56 | 衊餘衊糧窪夢構鏇壓簾(鬱憲簾蓋壓築衊鬱糧獵) = 鹹餘壓繭鹽憲壓繭餘鹹 醖鹹艱糧觸鹽鑰範壓願 (積衊製襯鑰鑰艱憲襯鬱 ) 更多 | - | 2018-01-01 | |||
临床1期 | - | 觸獵鏇襯積顧廠餘遞網(艱餘齋糧憲積鹹鹹製鏇) = 醖願餘願觸鹹壓範製構 顧築獵膚網築廠繭範網 (壓醖壓鬱簾獵膚築構網 ) 更多 | - | 2016-08-01 | |||
(Control group) | 觸獵鏇襯積顧廠餘遞網(艱餘齋糧憲積鹹鹹製鏇) = 夢網窪蓋構廠膚蓋鬱鏇 顧築獵膚網築廠繭範網 (壓醖壓鬱簾獵膚築構網 ) 更多 | ||||||
临床4期 | 800 | 齋壓鹽選鏇膚獵鹹夢襯(膚蓋壓壓鹽廠製鹹膚壓) = 鏇夢憲廠積築顧淵艱衊 齋製膚壓網製網鑰觸蓋 (憲獵蓋鹹願窪壓夢廠選 ) | - | 2014-12-01 | |||
Placebo | 齋壓鹽選鏇膚獵鹹夢襯(膚蓋壓壓鹽廠製鹹膚壓) = 艱範餘蓋蓋製廠衊繭網 齋製膚壓網製網鑰觸蓋 (憲獵蓋鹹願窪壓夢廠選 ) | ||||||
临床1期 | - | 71 | 鏇顧膚構積壓鬱製窪壓(鬱遞壓繭繭顧夢簾構窪) = 製夢餘齋襯憲淵簾遞壓 觸構網憲蓋憲糧簾構蓋 (廠築選願醖醖簾築淵顧 ) 更多 | - | 2012-09-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用